Meeting
2018 Genitourinary Cancers Symposium
Is BMI a risk factor for active surveillance progression in patients with prostate cancer diagnosed by MRI-Trus fusion biopsy?
Authors
Kareem Rayn
Urologic Oncology Branch, National Cancer Institute at the National Institutes of Health, Bethesda, MD
Kareem Rayn , Samuel Gold , Graham R. Hale , Joey Baiocco , Jonathan Bloom , Vladimir Valera , Brad J. Wood , Baris Turkbey , Peter A. Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 124)
DOI
10.1200/JCO.2018.36.6_suppl.124
Abstract #
124
Poster Bd #
F22
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
MRI-TRUS fusion-guided biopsy in obese patients: Does it reduce risk of prostate cancer upgrade on final pathology compared to systematic 12-core biopsy?
First Author: Samuel A Gold
Poster
2016 Gastrointestinal Cancers Symposium
Outcomes and toxicity in patients treated with bimodality or trimodality therapy for esophageal carcinoma with intensity modulated radiation therapy (IMRT).
First Author: Ajay Patel
Poster
2016 Genitourinary Cancers Symposium
MRI-US fusion targeted biopsy results in men with a history of prior cancer.
First Author: Cayce Nawaf
Poster
2023 ASCO Genitourinary Cancers Symposium
“It just makes sense to me”: Patient experiences with prostate MRI during prostate cancer active surveillance.
First Author: Ryan Sutherland